Log In
BCIQ
Print this Print this
 

Hemangeol, Hemangiol, propranolol

  Manage Alerts
Collapse Summary General Information
Company Laboratoires Pierre Fabre S.A.
DescriptionPediatric formulation of propranolol, a non-selective adrenergic receptor beta (ADRB) blocker
Molecular Target Adrenergic receptor beta (ADRB)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard Indication Cancer (unspecified)
Indication DetailsTreat infantile hemangiomas; Treat proliferating infantile hemangiomas requiring systemic therapy
Regulatory Designation U.S. - Orphan Drug (Treat proliferating infantile hemangiomas requiring systemic therapy);
EU - Standard Review (Treat infantile hemangiomas);
Japan - Orphan Drug (Treat infantile hemangiomas);
Australia - Orphan Drug (Treat infantile hemangiomas)
PartnerMaruho Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/21/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today